ESC Congress 2011

27 - 31 August 2011, Paris - France

Session Details

Clinical Trial Update I - Drug treatment
Sun 28 Aug 14:00 - 15:30 Unknown Clinical Trial and Registry Update, Scene@ESC - Sessions to be replayed, Webcast Paris - Zone F
Chairpersons: Stefan AGEWALL (Oslo, NO), Georgios PARCHARIDIS (Thessaloniki, GR)

Abstract Slides/e-posters Video Report

List of Presentations

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
14:001153KYOTO HEART Study: Cardiovascular protective effects of valsartan in high-risk hypertensive patients with chronic kidney disease: updated analysis of KYOTO HEART StudyTakahisa SAWADA (Kyoto, JP)
14:101154Discussant - KYOTO HEART Study: Cardiovascular protective effects of valsartan in high-risk hypertensive patients with chronic kidney disease: updated analysis of KYOTO HEART StudyJosep REDON (Valencia, ES)
14:151155ASCOT: Anglo-Scandinavian Cardiac Outcomes Trial: 10 year follow-up of the Lipid_lowering ArmlPeter S SEVER (London, GB)
14:251156Discussant - ASCOT: Anglo-Scandinavian Cardiac Outcomes Trial: 10 year follow-up of the Lipid_lowering ArmlGuy DE BACKER (St Martens Latem, BE)
14:301157ARISTOTLE: Efficacy and safety of Apixaban compared to Warfarin at different levels of INR control for stroke prevention in 18,202 patients with atrial fibrillation in the ARISTOTLE trialLars WALLENTIN (Uppsala, SE)
14:401158Discussant - ARISTOTLE: Efficacy and safety of Apixaban compared to Warfarin at different levels of INR control for stroke prevention in 18,202 patients with atrial fibrillation in the ARISTOTLE trialJean-Philippe COLLET (Paris, FR)
14:451159ROCKET AF: Prevention of stroke and systemic embolism using the oral direct factor Xa inhibitor Rivaroxaban compared with Warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairmentKeith FOX (Edinburgh, GB)
14:551160Discussant - ROCKET AF: Prevention of stroke and systemic embolism using the oral direct factor Xa inhibitor Rivaroxaban compared with Warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairmentStefan H HOHNLOSER (Frankfurt, DE)
15:001161RE-LY: Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY®) trialAntonio Miguel DANS (Manila, PH)
15:101162Discussant - RE-LY: Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY®) trialFreek VERHEUGT (Amsterdam, NL)
15:151163ONTARGET: Medication adherence and outcomes in high-risk cardiovascular patients in the ONTARGET trialMichael BOEHM (Homburg/Saar, DE)
15:251164Discussant - ONTARGET: Medication adherence and outcomes in high-risk cardiovascular patients in the ONTARGET trialLuigi TAVAZZI (Cotignola, IT)